Latest News and Press Releases

Die Zusammenarbeit kombiniert BioNTechs unternehmenseigene multimodulare Immuntherapie-Expertise mit Crescendos proprietärer Humabody® VH Plattform zur Entwicklung von Präzisionsimmuntherapien,...

Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based...

-- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi’s recently announced mRNA Center...

Pune, India, Dec. 15, 2020 (GLOBE NEWSWIRE) -- The global demand for mRNA vaccines & therapeutics market size, in terms of revenue, was worth of USD 587.7 million in 2019 and is expected to...

-- Lead candidate MRT5005 leverages Translate Bio’s proprietary LNP and mRNA platform and is the only clinical-stage mRNA therapeutic in development for the treatment of CF -- -- Second CF program,...

LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...

-- Expanded collaboration with partner Sanofi Pasteur for all infectious diseases further unites Translate Bio’s leading mRNA technology and large-scale manufacturing with Sanofi’s world class vaccine...

-- Pursuing development of mRNA vaccine against COVID-19 through expanded collaboration with Sanofi Pasteur -- -- Existing large-scale manufacturing capacity expected to help meet needs of...

-- FDA grants Rare Pediatric Disease designation for MRT5005 for treatment of cystic fibrosis –  -- Response to COVID-19 pandemic anticipated to cause interruptions in certain clinical trial...

NASHVILLE, Tenn., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...